Sarcopenia is associated with leukopenia in urothelial carcinoma patients who receive tislelizumab combined with gemcitabine and cisplatin therapy

ConclusionsPatients with sarcopenia were more likely to develop leukopenia after receiving T  + GC. There were no notable alterations observed in relation to anemia or thrombocytopenia. No significant difference was found between the sarcopenia group and non-sarcopenia group in terms of tumor response and grade 3–4 hematological toxicity.
Source: International Journal of Clinical Oncology - Category: Cancer & Oncology Source Type: research